These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28667408)

  • 1. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
    Tanaka H; Kanda M; Morita S; Taguri M; Nishikawa K; Shimada M; Muguruma K; Koeda K; Takahashi M; Nakamori M; Konno H; Tsuji A; Hosoya Y; Shirasaka T; Yamamitsu S; Sowa M; Kitajima M; Okajima M; Kobayashi M; Sakamoto J; Saji S; Hirakawa K
    Int J Clin Oncol; 2017 Dec; 22(6):1052-1059. PubMed ID: 28667408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
    Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
    Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
    Ishikawa T; Kawashima H; Ohno E; Matsubara H; Sasaki Y; Achiwa K; Kanamori A; Sumi H; Hirai T; Nonogaki K; Tsuzuki T; Kuroiwa M; Hattori M; Maruta S; Hiramatsu T; Ando M; Hashimoto S; Hirooka Y
    Oncology; 2019; 96(1):1-7. PubMed ID: 30368509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
    Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
    Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
    Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
    Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
    Sakuma K; Hosoya Y; Arai W; Haruta H; Ui T; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Hyodo M; Nagai H; Yasuda Y; Shirasaka T
    Int J Clin Oncol; 2010 Apr; 15(2):166-71. PubMed ID: 20195683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
    Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
    Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
    Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
    Koizumi W; Kurihara M; Nakano S; Hasegawa K
    Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.
    Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
    Br J Cancer; 2007 Aug; 97(4):458-63. PubMed ID: 17653073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
    Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
    Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
    Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
    Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
    Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
    Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.